Introduction: When directly exposed to various echinacea fractions, human leukocytes ex vivo are strongly stimulated to proliferate and to produce immunostimulation and inflammatory cytokines. A comparison of fractions containing lipoidal small molecules and high-molecular-weight water-soluble polysaccharides indicates that the latter are substantially more potent as immunostimulants. Echinacea purpurea (L.) Moench, E. angustifolia DC, and E. pallida (Nutt.), Nutt. extracts, and each plant part contain significantly potent constituents. Flow cytometric techniques were utilized.
INTRODUCTION
A fundamental problem that hinders the optimal use of certain herbal remedies is the lack of suitable assay methods. This lack makes it extremely difficult to determine appropriate dosages and administration intervals for even such very widely used herbal extracts and phytomedicines as echinacea. It is also difficult to assure practitioners and consumers that preparations available to them are uniform in effective content. 1 Echinacea (Echinacea spp.) has widespread use today for nonspecific immunostimulation [2] [3] [4] [5] [6] and is most often used in oral preparations for prevention or reduction of the symptoms of mild upper-respiratory infections. The herb is also used topically to promote wound healing, for treatment of vulvo-vaginal candidiasis, and for palliation of irritated and swollen skin patches. Echinacea use has grown to a substantial economic level and it is one of the most popular of the self-selected herbal remedies today. 7, 8 Echinacea products have often been assayed chemically for the content of this herb's lipophilic constituents without assurances that this relates to the potency or utility of these products. Indeed, there is no strong link between such a chemical marker to any biologic effect and material sold to the public has been shown in some recent work to be of very variable quality. 9 For example, echinacoside is often used as a chemical marker in extracts of E. angustifolia and E. pallida, but not of E. purpurea, even though it does not seem to have significant immunostimulant activity. 10, 11 Extracts of E. purpurea (aeral parts and/or subterranean parts) are generally standardized to total phenolic compounds calculated as the sum of cichoric acid, chlorogenic acid, caftaric acid, and caffeic acid.
Extraction and high-performance liquid chromatography (HPLC) examination of the lipophilic components do not necessarily reflect the potency of echinacea preparations. These techniques are valuable, however, because they help confirm species identity and the presence of adulterants. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, the polysaccharides in echinacea are not usually determined in this manner and therefore, the issue of their relative contribution to activity is yet to be settled.
Numerous papers attest to the in vitro activity of echinacea preparations on various cells of the immune system. 1, 3, [23] [24] [25] For example, using phagocytes, Wagner et al. confirmed the immunostimulant properties of echinacea toward a nonspecific immune response (non-antigen dependent), both in vitro (by human granulocytes incubated ex vivo with yeast cells) 26 and in vivo (as measured by carbon particle clearance by macrophages in mice). 27 Both the water-soluble, high-molecular-weight acidic, arabanoglucan-containing fractions 26, [28] [29] [30] [31] and the solvent-soluble, smaller-molecular-weight fractions containing polyunsaturated isobutylamides, phenolcarboxylic esters, and cichoric acid components were active. [32] [33] [34] [35] Later studies, using Caco-2-transport, demonstrated that the alkylamides were capable of membrane passage by passive processes, whereas caffeic acid conjugates were not so easily taken up. 36, 37 Cichoric acid was specifically found to be an active component. 27 The cell culture-derived and purified polysaccharides were confirmed to activate the phagocytes in human subjects as well as in human cells ex vivo. 25, [38] [39] [40] [41] Researchers have confirmed immunostimulant activity in infected mice by using the polysaccharides 25, 40 and also with an acidic arabinogalactan preparation from tissue cultures of E. purpurea. 42 Characterization of analogous polysaccharides from field-grown echinacea species has also been performed. 20, 21 Several recent studies of echinacea preparations in mice have given conflicting results-some positive, [43] [44] [45] [46] and others negative. 47, 48 A standardized root extract of E. angustifolia has been described that contains echinacoside (0.4%), isobutylamides (Ͻ0.1%), and polysaccharides (Ͼ5%). This material enhanced immune functions, as measured by enhanced proliferation rate and ␥-interferon production in murine T-lymphocytes, and reduced the mortality in normal and immune-suppressed mice infected with Candida albicans. 49 This study suggests that the immunostimulant action of echinacea is primarily mediated through T-cell stimulation, and is attributable to the presence of high-molecular-weight heterogalactan, in agreement with the work of Wagner et al. [28] [29] [30] These in vitro and animal results generally support activity on the part of both the small molecule organics and the polysaccharides, but they do not answer an important question. Which are the more active compounds in side-byside comparisons in the same test system? Thus, the question of relative potency remains unresolved. 26 Despite these and other generally supportive in vitro and in vivo studies, efficacy studies against upper-respiratorytract infections, including the common cold in the clinic, continue to produce conflicting results. 23, 50 Recent clinical trials often fail to record the origin or the potency of the product being studied. Furthermore, the doses chosen were often quite different-there being no generally accepted dosing schedule for echinacea. This has led to significant confusion, in that a number of studies failed to reveal measurable activity in humans, whereas a number of other studies demonstrate immunostimulatory action in patients with respiratory infections. 43, 51 Overall, there is a lack of consensus about the utility of echinacea preparations in preventing or curing infections. 23, [52] [53] [54] [55] [56] In a recent clinical study, daily oral administration of freshly pressed juice of the aerial parts of E. purpurea to 40 healthy adult male volunteers failed to produce an increase in the concentrations of T and B cells or of CD4ϩ and CD8ϩ subpopulations including naïve and memory lymphocytes and natural killer (NK) cells. The assay technique was flow cytometry. 57 The fresh pressed juice of the aerial parts is the form of E. purpurea generally available in Central Europe.
This newer study was designed to determine whether flow cytometry could measure immunostimulant activity present in echinacea and, if so, which species contained more activity, which plant part was the most active, and whether the organic soluble or the aqueous extractables are more active. 58, 59 Flow cytometric techniques are widely used to survey immune cell status and appear to offer a means of deciding these issues with ex vivo human clinical material. [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] 
EXPERIMENTAL SECTION*

General experimental procedures
Plant material was collected from wild stands in Kansas and adjoining states during the summer and Fall of 1999 and processed that year. Collection was performed under the supervision of Drs. Ralph Brooks, Craig Freeman, and Kelley Kindscher of the Kansas Biological Survey where voucher specimens are stored. † The material was freed of soil, air dried, kept as whole plant or fractionated into portions (leaves, stems, roots, flowers, etc.), ground into dry powders, and stored at Ϫ78°C in sealed plastic bags before extraction. The material obtained from field collections was mature stands of indeterminate age. Some additional material was purchased from American Herbs (P.O. Box 627, Ellettsville, IN 47429). This material was not independently verified as to species or age, however, our analyses did not differ significantly from those obtained through other sources. Significant amounts of material were also obtained from material field grown in Anhui Provence, China by the Pharmanex Corporation (Provo, UT), as were samples of freshly pressed and lyophilized juice of the roots of E. purpurea labeled FDEPJ. The fieldgrown material was 1 year old. The material was not tested by USP-NF methods and may not be of pharmacopoeial quality.
Extraction and fractionation
Process A: Ethanol extraction. Dried and powdered roots of E. purpurea (557.7 g) were extracted overnight at room temperature with six successive 1.8-L batches of ethanol. Evaporation under reduced pressure produced 54.0 g (9.7%) of an oily residue. Extraction of the dried and powdered flowering tops (992.4 g) produced 110.7 g of oily residue (11.1%), whereas extraction of the dried and powdered leaves and stems (1777 g) produced 98.3 g of oily residue (5.5%). Extraction of E. pallida (stems and leaves gave 3.5%; flowering tops 5.2%; roots 4.9%) and E. angustifolia (stems and leaves gave 4.8%; flowering tops 5.2%; roots 5.5%) produced analogous results.
Process B: Ethanol extraction followed by water extraction. Air-dried powdered E. purpurea root material (20 g ) recovered from the ethanol extraction procedure was extracted with deionized water (200 mL, 37°C) by maceration-filtration cycles using a gyrotory shaker; one cycle of 4 hours followed by a second of 18 hours. The cooled aqueous extract was lyophilized to produce 5.17 g of residue.
Similarly the stems and leaves produced 3.07 g and the flowerlets 4.3 g: E. pallida roots produced 2.79 g of water extract residue, 2.83 g from the flowerlets and 3.43 g from the stems and leaves. Similarly, E. angustifolia roots produced 1.87 g of ethanol-precipitated water extract residue and 1.87 g of residue from the ethanol supernatant, 4.78 g from the flowerlets and 4.10 g from the stems and leaves.
Process C: Extraction with 1:1 ethanol-water. E. purpurea flowerlet powder (20 g ) was extracted at 37°C twice with 200-mL portions of ethanol:water 1:1, the extracts combined, concentrated to one-third volume by rotary evaporation and then lyophilized to produce 4.03 g of extract residue. Similar treatment of the powdered stems and leaves produced 3.52 g of extract residue.
Process D: Water extraction followed by ethyl acetate partitioning. Powdered roots (20 g ) of E. purpurea were extracted 3 ϫ 200 mL of water (37°C). Half of the solution was lyophilized and the remainder extracted twice with equal volumes of ethyl acetate to remove the organic soluble components. The aqueous extract produced 3.51 g of residue. After ethyl acetate partitioning, a residue of 2.82 g of water solubles was produced. Evaporation of the dried organic layer (sodium sulfate treatment followed by filtration) under reduced pressure gave a residue (0.020 g, 0.1%). Amounts are given in Table 1 .
Process E. Dried and ground plant material (20 g) or lyophilized pressed fresh juice (10 g) was extracted by maceration-filtration until exhaustion with the following sequence of solvents: hexane, benzene, ether, chloroform, ethyl acetate, ethanol and then water, resulting in the weighed residues: hexane 0.14 g, benzene 0.02 g, ether 0.01 g, chloroform 0.01 g, ethyl acetate 0.01 g, ethanol 0.09 g, and water 6.23 g.
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*An expanded version of this experimental section that contains extensive experimental values for immunostimulation by various plants and plant parts as a function of concentration can be obtained electronically by request to the corresponding author (mitscher@ku.edu).
† Species collection was assisted by and identification was verified by Drs. Kelly Kindscher, Ralph Brooks, and Craig Freeman of the Kansas Biological Survey, Lawrence. Voucher specimens are deposited in the University of Kansas Herbarium.
Process F: Water extraction followed by ethanol drowning: E. purpurea dried and powdered root extract (not previously extracted with ethanol-in contrast to process B) (20 g ) was extracted with water and then diluted with ethanol as described in process B, to produce 4.61 g (20.8%) of ethanol soluble material while the precipitate was taken up in water and lyophilized to produce 4.09 g (20.5%) of residue. Similar processing produced 1.27 g of ethanol precipitate and 1.75 g of residue from the supernatant from the stems, 3.68 g and 4.33 g, respectively, from the leaves and 2.16 g and 2.90 g, respectively from the flowerlets.
In a second set of experiments, air-dried powdered roots of E. purpurea (20 g ) were extracted with water (200 mL, 37°C, 4 hours) followed by an 18-hour extraction with a fresh warm solution of 200 mL of distilled water. The aqueous extracts were combined and divided into two equal portions. Lyophilization of one half produced a 3.51-g residue (17.6%).
E. angustifolia root powder (20 g) was extracted with water (2 ϫ 200 mL, 37°C, 18 hours), combined and diluted with 2 L of ethanol. After standing for 5.5 hours, the precipitate was removed to produce 2.14 g of residue. Evaporation of the supernatant produced 2.29 g of residue.
HPLC conditions for analysis of Echinacea species extracts. For hydrophilic analyses, the mobile phases used were: A, 50 mmol/L NaH 2 PO 4 at pH 2.9 and B, 1% 0.1 N H 3 PO 4 in acetonitrile. The flow rate was 1.5 mL/min. A linear gradient was used adding phase B from 5% to 25% over 7 minutes, held at 25% for 2 minutes and 25-5% in 1 minute, equilibrated for 5 minutes. The columns were 3 m LiChrospher 100 RO-18, 75 ϫ 4.6-mm cartridge and 5 mol/L LiChrospher RP-18, 4 ϫ 4.6-mm guard cartridge. The detection wavelength was 320 nm.
For lipophilic analyses, the mobile phases used were: A, water and B, acetonitrile. The flow rate was 1.1 mL/minute and a linear gradient was used adding 40-80% B in 15 minutes, 80-40% in 1 minute, and equilibration for 6 minutes. The columns used were 3 m LiChrospher 100 RP-18, 75 ϫ 4.6-mm cartridge and a 5 m LiChrospher RP-18, 4 ϫ 4.6-mm guard cartridge. The detection wavelength was 260 nm.
Authentic samples of cichoric acid (retention time ϭ 3.73 minutes), echinacoside (retention time ϭ 5.85 minutes), chlorogenic acid, and a representative tetraene mixture (retention time ϭ 7.51 minutes) were obtained from Ottawa (Ontario, Canada) University and used as identification controls. This material was HPLC grade and showed only minor satellite peaks upon HPLC examination.
Flow cytometric measurements.
The immunostimulation assays were measured in triplicate using a Becton Dickinson (San Jose, CA) FACScan I flow cytometer and associated software (BD Immunocytometry systems FACScan software version 4.1 with data analysis using CellQuest Program [Becton Dickinson] version 3.2.1). The specific protocol utilized freshly drawn human blood collected in a sodium heparin vacuo-container by professional medical personnel from volunteers immediately prior to the experiment. The volunteers were healthy adults selected from the authors of this work. In preliminary work, Ms. Linda Steele, a healthy adult, also voluntarily provided blood samples. Appropriate concentrations of test samples dissolved in dimethyl sulfoxide (DMSO) were added to 200 L of heparinized blood after being mixed with 50 L of phosphate buffer. The resulting mixture was vortexed and incubated at 37°C for 5 hours in a CO 2 incubator to allow adequate time for immune cell stimulation.
After the cell stimulation period, 50 L of the stimulated blood samples were added to each of fresh 12 ϫ 75-mm tubes containing the various reagent cocktails, vortexed, and incubated at room temperature for 30 minutes in the dark at room temperature. Reagent cocktails consisted of 20 L of CD4FITC/CD69PE/CD3PerCP expressed on the helper/ inducer T-lymphocyte subset; CD8FITC/CD69/PE/CD3-PerCP expressed on the human suppressor/cytotoxic T-lymphocytes and on a subset of NK lymphocytes; CD19FITC/ CD69PE/CD45PerCP expressed on B-lymphocytes; or CD56FITC/CD69PE/CD45PerCP expressed on NK lymphocytes. Next, 450 L of 1 ϫ FACS lysing solution was added to each tube which was then vortexed gently and incubated in the dark at room temperature for 30 minutes. Next, 450L of 1 ϫ FACS Lysing Solution (Becton Dickinson) was added to each tube. These were vortexed gently and incubated in the dark at room temperature for 20 min-PILLAI ET AL. 628 
RESULTS
The lipophilic small molecules (echinacoside, cichoric acid, the polyenes, etc.), were extractable from the plant material with ethanol, but not the water-soluble polysaccharides. Accordingly, dried and ground samples of the separated roots, stem/leaves, and flowerlets of wild-type samples of E. purpurea, E. angustifolia, and E. pallida were extracted with ethanol (process A) and the concentrates were tested against CD4ϩ cells. The ethanol-soluble material was barely more active than the solvent controls even at high doses (Table 2) .
Next, the ethanol-depleted plant material (E. purpurea roots) was dried and extracted with water (process B). The lyophilized aqueous extracts were significantly active, stimulating CD4ϩ cells by about 24% at 100 g/mL concentration. When concentrated and diluted fourfold with ethanol, a precipitate was obtained. The precipitate was more active than the water extract itself, stimulating CD4ϩ cells by 40.76% at 100 g/mL concentration. The supernatant hydro-alcoholic soluble material containing the remaining solvent soluble organics was significantly less active. It stimulated CD4ϩ cells only by about 8% at 100 g/mL concentration as compared to 3% for the solvent controls. Therefore, the bulk of the immunostimulatory activity resides in water-soluble material. The rest of the experiments confirm this finding.
Extracts of fresh stems and leaves from E. purpurea using a 1:1 solution of ethanol in water (process C) showed comparatively little activity in the extract (6.49% stimulation of CD4ϩ cells at 100 g/mL as compared to 4% for the solvent controls; and the activity of the extract did not rise to its maximum at 9.77% until a concentration of 1600 g/mL was reached). Thus, the bulk of the activity failed to be extracted by a 50% ethanol solution.
Next, E. purpurea root powder was extracted with water and partitioned several times with ethyl acetate (process D) in order to remove the low-molecular-weight organics. Again the activity predominantly remained in the water layers (peak stimulation of 41.56% at 400 g/mL). Ethanol precipitation of this material produced a dried powder stimulating CD4ϩ cells 47.53% at a peak concentration of 200 g/mL. The ethanol layer was evaporated to produce a residue active only at 11.6% at a concentration of 3200 g/mL. Analogous treatment of E. purpurea stem plus leaf powder produced an aqueous extract 36.39% active at its peak dilution (100 g/mL). After ethyl acetate partitioning, the aqueous layer stimu-IMMUNOSTIMULANT ACTIVITY OF ECHINACEA 629 lated CD4ϩ cells maximally 39.48% at 200 g/mL concentration. The ethyl acetate layer was weakly active. Similar findings were observed using the various plant parts of E. angustifolia. In another experiment probing this proposition, fresh E. purpurea root powder was extracted sequentially (with drying in between) with hexane, benzene, ethyl ether, chloroform, ethyl acetate, ethanol, and then water (process E). Each successive organic solvent extracted only a minor percentage of active material ranging from 3.73% stimulation at 100 g/mL after benzene extraction (barely above the solvent control) to 8.71% stimulation with ethyl acetate extraction. The bulk of the active material was extracted with the water (34.37% stimulation at 100 g/mL). This is entirely consistent with the previous findings.
Parallel serial solvent extraction of lyophilized fresh juice expressed from E. purpurea gave similar results (24.67% stimulation at 100 g/mL with the untreated lyophilizate, compared to 23.50% stimulation at that concentration, after washing with ethyl acetate). The solvent extract had removed very weakly active material testing at 6.53% stimulation at the same concentration compared with solvent control values of ϳ5.4%. Furthermore, after sequential extraction with the same solvent sequence, aqueous extraction produced material active at 20.88% at a concentration of 100 g/mL.
Next, a comparison was made between lyophilizing the aqueous extracts of E. purpurea roots and precipitating the aqueous extracts with ethanol. Essentially, equivalent results were obtained with these two methods. The lyophilized water extract gave a peak stimulation of CD4ϩ cells of 46.55% at a concentration of 100 g/mL, whereas the ethanol precipitated water extract gave a peak stimulation of 47.53% at 200 g/mL. Interestingly, measurable stimulation was found at concentrations as low as 24 ng/mL. Given the convenience of the ethanol precipitation, most of the remaining experiments were performed in this mode: first extracting with water, precipitating the high-molecular-weight and polar extractives with ethanol (process F), and then analyzing both fractions.
A survey was made of the response of various immune cell types to ethanol-precipitated aqueous plant part extracts from various echinacea species. Each plant part produced high levels of stimulation (at nanogram concentrations) against all of the cell types tested (CD4ϩ, CD8ϩ, CD19ϩ, and CD56ϩ). In all cases measured, the rank order of sensitivity toward echinacea extracts was CD19ϩ Ͼ CD56ϩ Ͼ CD4ϩ Ͼ CD8ϩ. The activity peak was generally at 100 g/mL and significant activity was still measurable at 24 ng/mL concentrations. The peak stimulation values for each of the plants and plant parts tested at 100 g/mL are listed in Table 3 .
In all of these experiments, freshly drawn human blood from uninfected individuals was used. This was verified by (1) the control values and (2) the capacity of the immune cells to be further stimulated, upon presentation with the appropriate concentrations of the challenge substances.
The plants were either in part collected in the wild (and so were of unknown biologic age) or from cultivated material, only 1 year of age. There was no significant difference in the extractable immunostimulatory activity based on age. For aboveground material, age is not generally considered significant but root material generally is collected after 3 years of age for medicinal purposes. Thus, the data from the roots in this study should be considered with caution because they may not be representative of commercially available medicinal products used in a clinical setting. Another significant inference is that processing using the rather simple bulk processes used in process F would remove much extraneous and even potentially harmful material in an inexpensive manner, leading to a well-standardized product of defined potency and consistency.
The bioactive ethanol precipitates were reasonably stable to heat or standing. Potency was maintained with minimal loss upon heating at 100°C for an hour and upon storage at 37°C for 60 days.
In addition, we examined whether some portion of the activity is caused by proteins and assayed for protein content using the Coomassie blue method. By this method, proteins were found to comprise about 10% of the active fractions. In preliminary experiments, to be detailed in a subsequent report, a highly active ethanol precipitate was chromatographed over a size exclusion Superdex 75 column (GE Healthcare Bio-sciences, Piscataway, NJ) in water. The progress of the elution was monitored by ultraviolet absorption and by anthrone reaction (for sugars). The most active fractions were strongly anthrone positive and ultraviolet negative, arguing in favor of the polysaccharides being responsible for the bulk of the immunostimulatory action rather than proteins. Furthermore, the activity of the extracts was stable to heating at 100°C for 15 minutes. Only an unusual protein would survive this. CD69 (cluster determinant 69) is the first cytokine expressed after stimulation and remains measurable from about 6-24 hours. It appears on the surface of all (T, B, and NK) activated leukocytes, and its increase indicates that these cells are maturing and proliferating in response to immunogenic stimuli. 58 Other cytokines appear later, and individual cells of each different response type were quantitated using selected stains by appropriate gating of the instrumental response. 59 Control measurements were made for comparative purposes in each series using cells from the same source after exposure to appropriate concentrations of phytohemagglutinin, phorbol myristyl acetate, or CD2/CD2R as controls. RPMI-1640 medium, 2% DMSO in RPMI-1640 medium, and cyclosporin A were used as baseline negative controls.
PILLAI ET AL. 630
Fluorescent antibody stain CD4FITC/CD69PE/CD3-PerCP binds to class II molecules of the major histocompatibility complex (MHC) antibodies expressed on the surface of the helper/inducer T-lymphocyte subset (CD3 ϩ CD4 ϩ ), the primary receptor for human immunodeficiency virus. Fluorescent antibody stain CD69 PE/CD3 PerCP binds to a very early human lymphocyte activation antigen on each cell type as well as platelets. Fluorescent antibody stain CD8FTIC/CD69PE/CD3PerCP binds to class I MHC molecules expressed by human suppressor/cytotoxic T-lymphocytes and on a subset of NK lymphocytes. The CD3 component of these stains reacts with a multiprotein complex associated with T cells. Fluorescent antibody stain CD56FTIC/CD69PE/CD45PerCP binds to the neural cell adhesion molecule expressed on NK lymphocytes mediating non-MHC-restricted cytotoxicity. Fluorescent antibody stain CD19FITC/CD69/CD45PerCP binds to antibodies present on human B cells. Unfortunately, at the time these studies were performed, specific fluorescent antibody stains were unavailable for macrophages.
DISCUSSION
The range-finding experiments are consistent with the classical folkloric use of echinacea. Having thus established beyond a reasonable doubt that the bulk of the immunostimulant activity of echinacea plant parts and species detectable with this method was extractable with water and not with organic solvents, these findings suggest strongly that the main immunostimulatory activity of echinacea resides in the water-soluble materials expected to contain the polyglycans analogous to those reported upon by Wagner et al. 26 Examination of the lyophilized fresh juice produced analogous results. This is important because the European preference is for administration of echinacea in this form (preserved with alcohol). The alcohol extracts were considerably less active. Preservation of juice with alcohol should not be troublesome provided that any material that separates is consumed and not discarded. Taken together, these findings suggest that the polyglycans contribute more to the bioactivity of echinacea preparations than the contributions of the small molecules. The various parts of the plants (leaves, stems, flowering tops, and roots) all contain substantial immunostimulatory activity. The species examined (E. purpurea and E. angustifolia) were significantly active. Therefore, a preference for E. purpurea is also not consistent with our findings.
The results of a dilution series in each case produced dose-response curves. A maximal stimulation response was observed and significantly higher concentrations of extract led to a decrease in response (Fig. 1) . These data strongly suggest that there is a productive dosage range that should be used in administering echinacea and that low doses would be expected to be ineffective. High doses produce either cellular immunologic fatigue or outright cellular toxicity. The data also suggest that immunocompetent patients presenting with respiratory infections would likely have their immune cells already stimulated. Thus, the use of echinacea preparations in their treatment would probably produce minimal further benefits or even combat their immune cells, because the patient's system has already been activated and proven incapable of handling the infection. 25, [70] [71] [72] [73] [74] In a preliminary experiment using the Riboquant methodology for identifying cytokines, produced in response to stimulation of various cell types, it was shown by us that T cells, stimulated by echinacea extracts, produced enhanced quantities of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), onchostatin M (OSM), lymphotoxin ␤ (LT␤), interferon-gamma (IFN␥), regulated on activation, normal T-expressed and presumably secreted (RANTES) and macrophage inflammatory protein ␤ (MIP␤); B cells produced LT␤ and MIP␤; and NK cells produced IFN␥. The macrophages produced GM-CSF, IL-6, OSM, MIP1␣, IL-8, IL-1␣, IL-1␤, and IL-1RA. Liberation of these cytokines is consistent with activation of components of the immune system. The versatility of T cells and macrophage stimulation is in agreement with the work of Wagner et al., 26 who used carbon particle engulfment methodology. Concerns have been expressed that the high-molecularweight glucans from echinacea preparations may not be absorbed when taken orally. However, the gut epithelial barrier does not completely prevent luminal antigens from entering the tissues. This is variously attributed to breaks in villus tips, where cells are being shed, and to Peyer's patches of lymphoid cells and antigen-presenting dendritic cells that penetrate between gut epithelial cells. The barrier in the gut to uptake of antigens thus limits but does not exclude them from entering the tissues. Thus, the immune system constantly samples gut antigens. [75] [76] [77] [78] [79] Material analogous to echinacea polysaccharides is capable of absorption, processing, and distribution to the cells of the immune system after oral administration. Furthermore, the low-molecular-weight lipoidal organics have structural characteristics compatible with passive absorption from the gut. 80 Thus, failure to detect activity in some echinacea studies cannot be rationalized with confidence as merely representing a failure of absorption.
Finally, it should be noted that the use of tinctures prepared from echinacea and the practice of stabilizing aqueous echinacea extracts against fungal growth, by addition of alcohol, would both appear to be potentially risky practices. According to our results, the most potent material could be precipitated from such solutions so that any precipitate that formed should not be discarded before use. Thus, the variable results obtained in the clinic may stem in part from not knowing and controlling this effect.
CONCLUSIONS
Biologically based assays are likely to be of greater value in determining the potential value of echinacea preparations than chemical assays, based upon individual chemical constitutents, because it is likely from the available literature and the present work that more than one component is responsible for the immunostimulant properties of echinacea preparations. A reliable end-use-related quantitative bioassay would appear to go a long way toward resolving confusion about the immunostimulatory properties of echinacea preparations. The present study demonstrates the use of flow cytometry to show a link between a chemical signal (polysaccharide) in echinacea and the biologic immunostimulatory effect that has therapeutic relevance. We have presented strong evidence for this immunostimulant property of the polysaccharides in echinacea. The chemical characterization of this active material will be the subject of the next report on this work.
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SUPPLEMENTARY APPENDIX: EXPERIMENTAL DATA
Immunostimulation of extracts using process A
Fractions from E. purpurea roots by ethanol extraction. CD4/CD69/CD3 panel; 2% dimethyl sulfoxide (DMSO) in Roswell Park Memorial Institute (RPMI) ϭ 2.10%, cyclosporin A (CspA) (10 g/mL) ϭ 2.20%, phorbol myristyl acetate PMA (50 ng/mL) ϭ 31.07%, CD2/CD2R (5 g/250 L) ϭ 11.74%. Extract at 250 g/mL ϭ 1.47%, 500 g/mL ϭ 1.89%, 750 g/mL ϭ 2.37%, 1000 g/mL ϭ 2.97%. E. purpurea stems and leaves: extract vs. CD4ϩ @ 250 g/mL ϭ 1.81%, 500 g/mL ϭ 3.56%, 750 g/mL ϭ 0.83%, 1000 g/mL ϭ 2.63%. E. purpurea flowerlets: 250 g/mL ϭ 2.89%, 500 g/mL ϭ 1.07%, 750 g/mL ϭ 3.35%, 1000 /mL ϭ 2.28%.
Fractions from E. angustifolia roots by ethanol extraction. extract at 250 g/mL ϭ 1.61%, 500 g/mL ϭ 1.53%, 750 g/mL ϭ 1.87%, 1000 g/mL ϭ 2.21%. E. angustifolia stems and leaves: extract at 250 g/mL ϭ 0.00%, 500 g/mL ϭ 0.00%, 750 g/mL ϭ 0.00%, 1000 g/mL ϭ 0.00%. E. angustifolia flowerlets: 250 g/mL ϭ 1.86%, 500 g/mL ϭ 0.94%, 750 g/mL ϭ 2.49%, 1000 g/mL ϭ 2.60%.
Fractions from E. pallida roots by ethanol extraction. extract at 250 g/mL ϭ 0.75%, 500 g/mL ϭ 1.25%, 750 g/mL ϭ 1.52%, 1000 g/mL ϭ 1.22%. E. pallida stems and leaves: 250 g/mL ϭ 1.28%, 500 g/mL ϭ 0.26%, 750 g/mL ϭ 1.56%, 1000 g/mL ϭ 2.16%. E. pallida flowerlets: 250 g/mL ϭ 1.26%, 500 g/mL ϭ 1.09%, 750 g/mL ϭ 4.44%, 1000 g/mL ϭ 0.65%.
Immunostimulation of extracts using process B
Fractions from ethanol-depleted E. purpurea root powder. CD4/CD69/CD3 panel: 2% DMSO in RPMI ϭ 3.28%, RPMI ϭ 2.65%, CspA (10 g/mL) ϭ 3.38%, PMA (50 ng/mL) ϭ 95.08%, CD2/CD2R (5 g/250 L) ϭ 54.34%. Water extract residue at 25 g/mL ϭ 24.27%, 50 g/mL ϭ 24.09%, 100 g/mL ϭ 23.97%, 200 g/mL ϭ 22.07%, 400 g/mL ϭ 19.97%, 800 g/mL ϭ 24.21%, 1600 g/mL ϭ 22.52%, 3200 g/mL ϭ 46.36%: ethanol precipitate from water extraction at 25 g/mL ϭ 32.29%, 50 g/mL ϭ 40.39%, 100 g/mL ϭ 40.76%, 200 g/mL ϭ 35.03%, 400 g/mL ϭ 27.42%, 800 g/mL ϭ 25.44%, 1600 g/mL ϭ 25.44%, 3200 g/mL ϭ 41.74%: ethanol supernatant vs CD4ϩ at 25 g/mL ϭ 5.90%, 50 g/mL ϭ 6.98%, 100 g/mL ϭ 8.11, 200 g/mL ϭ 9.88%, 400 g/mL ϭ 9.88%, 800 g/mL ϭ 9.79%, 1600 g/mL ϭ 9.04%, 3200 g/mL ϭ 8.96%.
Immunostimulation of extracts using process C
Immunostimulation against CD4ϩ cells of E. purpurea stems and leaves by a 1:1 solution of ethanol in water (process C). DMSO ϭ 4.02%, RPMI ϭ 4.12%, CspA ϭ 4.86%, PMA ϭ 99.40%, phytohemagglutinin (PHA) ϭ 11.0, CD2/CD2R ϭ 15.09%. Extract at 25 g/mL ϭ 4.83%, 50 g/mL ϭ 5.63%, 100 g/mL ϭ 6.49%, 200 g/mL ϭ 6.35; 400 g/mL ϭ 6.61%, 800 g/mL ϭ 7.10%, 1600 g/mL ϭ 9.77%, 3200 g/mL ϭ 9.53%.
Immunostimulation of extracts using process D
Fractions from E. purpurea roots using process D. DMSO ϭ 3.28%, RPMI ϭ 2.65%, CspA ϭ 3.38%, PMA ϭ 95.08%, CD2/CD2R ϭ 54.34%. Aqueous extract vs. CD4ϩ cells after ethyl acetate partitioning at 25 g/mL ϭ 39.33%, 50 g/mL ϭ 41.92%, 100 g/mL ϭ 35.21%, 200 g/mL ϭ 40.92%, 400 g/mL ϭ 41.56%, 800 g/mL ϭ 36.53%, 1600 g/mL ϭ 32.58%, 3200 g/mL ϭ 29.59%. Ethanol precipitated aqueous fraction at 25 g/mL ϭ 39.85%, 50 g/mL ϭ 42.20%, 100 g/mL ϭ 46.46%, 200 g/mL ϭ 47.53%, 400 g/mL ϭ 44.82%, 800 g/mL ϭ 41.41%, 1600 g/mL ϭ 30.54%, 3200 g/mL ϭ 24.16%. Ethanol supernatant residue at 25 g/mL ϭ 3.65%, 50 g/mL ϭ 4.85%, 100 g/mL ϭ 6.07%, 200 g/mL ϭ 6.24%, 400 g/mL ϭ 9.36%, 800 g/mL ϭ 9.66%, 1600 g/mL ϭ 11.47%, 3200 g/mL ϭ 11.60%.
Fractions from E. purpurea stems and leaves using process D. Aqueous extract at 25 g/mL ϭ 33.54%, 50 g/mL ϭ 33.59%, 100 g/mL ϭ 36.39%, 200 g/mL ϭ 35.99%, 400 g/mL ϭ 34.63%; 800 g/mL ϭ 29.27%, 1600 g/mL ϭ 26.70%, 3200 g/mL ϭ 27.91%. Ethyl acetate layer, 25 g/mL ϭ 6.22%, 50 g/mL ϭ 5.18%, 100 g/mL ϭ 4.61%, 200 g/mL ϭ 3.55%, 400 g/mL ϭ 4.05%, 800 g/mL ϭ 4.87%, 1600 g/mL ϭ 4.85%. Ethyl acetate partitioned aqueous layer, 25 g/mL ϭ 25.31%, 50 g/mL ϭ 34.52%, 100 g/mL ϭ 36.08%, 200 g/mL ϭ 39.48%, 400 g/mL ϭ 34.67%, 800 g/mL ϭ 32.10%, 1600 g/mL ϭ 28.10%, 3200 g/mL ϭ 26.27%.
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Fractions from E. angustifolia roots against CD4ϩ cells. DMSO ϭ 4.24%, RPMI ϭ 6.01%, CspA 
Immunostimulation of extracts using process E
Immunostimulation of fractions from serial extraction of E. purpurea roots. Hexane soluble at 100 g/mL ϭ 5.32%, 200 g/mL ϭ 6.12%, benzene soluble at 100 g/mL ϭ 3.73%, 200 g/mL ϭ 5.59%, ethyl ether soluble at 100 g/mL ϭ 5.33%, 200 g/mL ϭ 6.05%, chloroform soluble at 100 g/mL ϭ 8.23%, 200 g/mL ϭ 6.76%, ethyl acetate soluble at 100 g/mL ϭ 8.71%, 200 g/mL ϭ 7.89%, ethanol soluble at 100 g/mL ϭ 4.97%, 200 g/mL ϭ 4.48%, water soluble at 100 g/mL ϭ 34.37%, 200 g/mL ϭ 42.36%.
Immunostimulation against CD4ϩ cells of fractions from serial extraction of lyophilized fresh E. purpurea expressed juice (obtained from the Pharmanex Corporation labeled as FDEPJ)
. Untreated lyophilizate as received: DMSO ϭ 5.55%, RPMI ϭ 5.29%, CspA ϭ 7.94%, PMA ϭ 29.44%, CD2/CD2R ϭ 42.98, PHA ϭ 44.30%. Treated extract at 12.5 g/mL ϭ 15.21%, 25 g/mL ϭ 14.7%, 50 g/mL ϭ 19.85%, 100 g/mL ϭ 24.67%, 200 g/mL ϭ 28.54%, 400 g/mL ϭ 30.58%, 800 g/mL ϭ 34.59; 1600 g/mL ϭ 34.76%.
Lyophilizate after ethyl acetate extraction: DMSO ϭ 5.55%, RPMI ϭ 5.29%, CspA ϭ 7.94%, PMA ϭ 29.44%, CD2/CD2R ϭ 42.98, PHA ϭ 44.30%. Treated extract at 12.5 g/mL ϭ 15.93%, 25 g/mL ϭ 17.15%, 50 g/mL ϭ 13.90%, 100 g/mL ϭ 23.50%, 200 g/mL ϭ 28.35%; 400 g/mL ϭ 27.74%, 800 g/mL ϭ 31.04%, 1600 g/mL ϭ 27.80%.
Ethyl acetate extractive at 12.5 g/mL ϭ 5.07%, 25 g/mL ϭ 6.68%, 50 g/mL ϭ 5.68%, 100 g/mL ϭ 6.53%, 200 g/mL ϭ 4.25%; 400 g/mL ϭ 5.54%, 800 g/mL ϭ 4.12%, 1600 g/mL ϭ 5.45%.
Lyophilyzate after sequential extraction with hexane, benzene, ethyl ether, chloroform, ethyl acetate, and ethanol: DMSO ϭ 5.55%, RPMI ϭ 5.29%, CspA ϭ 7.94%, PMA ϭ 29.44%, CD2/CD2R ϭ 42.98, PHA ϭ 44.30%. Treated extract at 12.5 g/mL ϭ 12.24%, 25 g/mL ϭ 13.86%, 50 g/mL ϭ 16.51%, 100 g/mL ϭ 20.88%, 200 g/mL ϭ 31.32; 400 g/mL ϭ 36.50%, 800 g/mL ϭ 33.89%, 1600 g/mL ϭ 32.05%.
Comparison of water extraction of E. purpurea roots followed by ethanol precipitation with water extraction not followed by ethanol precipitation. DMSO ϭ 3.28%, RPMI ϭ 2.65%, CspA ϭ 3.38%, PMA ϭ 95.08%, CD2/CD2R ϭ 54.34%, extract precipitated with alcohol vs CD4ϩ at 25 g/mL ϭ 39.85%, 50 g/mL ϭ 42.20%, 100 g/mL ϭ 46.46, 200 g/mL ϭ 47.53%, 400 g/mL ϭ 44.82%, 800 g/mL ϭ 41.41%, 1600 g/mL ϭ 30.54%, 3200 g/mL ϭ 24.16%. Water extract without subsequent ethanol precipitation vs. CD4ϩ at 25 g/mL ϭ 41.36%, 50 g/mL ϭ 41.95%, 100
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g/mL ϭ 46.55, 200 g/mL ϭ 45.31%, 400 g/mL ϭ 44.52%, 800 g/mL ϭ 41.24%, 1600 g/mL ϭ 35.36%, 3200 g/mL ϭ 27.98%.
In an attempt to reach an endpoint, a second experiment was performed using process C and Pharmanex E. purpurea root product lot no. 991,011. DMSO ϭ 5.83%, RPMI ϭ 6.72%, CspA ϭ 7.25%, PMA ϭ 99.20%, PHA ϭ 16.98%, CD2/CD2R ϭ 47.25%, extract vs CD4ϩ at 48 ng/mL ϭ 13.40%, 97.5 ng/mL ϭ 17.12%, 195 ng/mL ϭ 20.78.
In a third experiment attempting to reach an endpoint by using process C, DMSO ϭ 2.50%, RPMI ϭ 2.42%, CspA ϭ 2.79%, PMA ϭ 99.60%, PHA ϭ 3.57%, CD2/CD2R ϭ 25.35%, extract vs CD4ϩ at 38 pg/mL ϭ 2.35%, 1.5 ng/mL ϭ 2.98%, 6.1 ng/mL ϭ 3.41, 24.4 ng/mL ϭ 10.03%, 98.5 ng/mL ϭ 23.41%, 390 ng/mL ϭ 35.57%, 1.65 g/mL ϭ 43.81%, 6.25 g/mL ϭ 44.24%, 25 g/mL ϭ 44.87%, 100 g/mL ϭ 41.16%, 400 g/mL ϭ 37.19%, 1600 g/mL ϭ 22.47%.
Immunostimulation of extracts using process F
Preparation of ethanol precipitates from water extracts of various plant parts of E. purpurea (Pharmanex lot. 991,011): roots. DMSO ϭ 5.83%, RPMI ϭ 6.72%, CspA ϭ 7.25%, PMA ϭ 99.20%, PHA ϭ 16.98, CD2/CD2R ϭ 47.25%. Root extract vs CD4ϩ at 6.25 g/mL ϭ 53.52%, 12.5 g/mL ϭ 59.53%, 25 g/mL ϭ 65.21%. Stem extract vs CD4ϩ at 6.25 g/mL ϭ 47.15%, 12.5 g/mL ϭ 53.71%, 25 /mL ϭ 57.23%. Leaf extract at 6.15 g/mL ϭ 55.44%, 12.5 g/mL ϭ 57.75%, 25 g/mL ϭ 58.20%. Flowerlet extract at 6.25 g/mL ϭ 57.77%, 12.5 g/mL ϭ 57.81%, 25 g/mL ϭ 65.38%.
In the remaining experiments, water extraction followed by ethanol precipitation was used. Water was removed from the precipitate by centrifugation, then the residue was suspended in a small amount of deionized water and then lyophilized.
Testing of the ethanol precipitate from E. purpurea flowerlets against various immune cell types. 2% DMSO in RPMI ϭ 2.00%, RPMI ϭ 4.40%, CspA (10 g/mL) ϭ 2.88%, PMA (50 ng/mL) ϭ 98.77%, CD2/CD2R (5 g/250 L) ϭ 40.204%.
Against CD4ϩ cells. Ethanol precipitate at 0.012 g/mL ϭ 12.37%, 0.024 g/mL ϭ 13.50%, 0.049 g/mL ϭ 17.36%, 0.098 g/mL ϭ 21.99%, 0.195 g/mL ϭ 26.58%, 0.390 g/mL ϭ 29.36%, 0.780 g/mL ϭ 35.64%, 1.560 g/mL ϭ 40.31%, 3.125 g/mL ϭ 39.68%, 6.250 g/mL ϭ 50.13%, 12.50 g/mL ϭ 51.94%, 25.00 g/mL ϭ 61.99%, 50.00 g/mL ϭ 62.75%, 100.0 g/mL ϭ 69.33%, 200 g/mL ϭ 68.53%, 400 g/mL ϭ 64.25%, 800.0 g/mL ϭ 57.72%, 1600 g/mL ϭ 47.61%.
Against CD8ϩ cells. 2% DMSO in RPMI ϭ 5.29%, RPMI ϭ 5.23%, CspA (10 g/mL) ϭ 5.74%, PMA (50 ng/mL) ϭ 98.32%, CD2/CD2R (5 g/250 L) ϭ 26.603%. Precipitate at 0.012 g/mL ϭ 15.96%, 0.024 g/mL ϭ 17.01%, 0.049 g/mL ϭ 20.19%, 0.098 g/mL ϭ 23.31%, 0.195 g/mL ϭ 26.96%, 0.390 g/mL ϭ 35.21%, 0.780 g/mL ϭ 35.63%, 1.560 g/mL ϭ 40.38%, 3.125 g/mL ϭ 39.99%, 6.250 g/mL ϭ 49.39%, 12.50 g/mL ϭ 49.86%, 25.00 g/mL ϭ 59.66%, 50.00 g/mL ϭ 57.91%, 100.0 g/mL ϭ 62.40%, 200.0 g/mL ϭ 67.48%, 400.0 g/mL ϭ 56.08%, 800.0 g/mL ϭ 42.98%, 1600 g/mL ϭ 29.88%. Against CD19ϩ cells. 2% DMSO in RPMI ϭ 7.37%, RPMI ϭ 8.85%, CspA (10 g/mL) ϭ 8.06%, PMA (50 ng/mL) ϭ 98.82%, CD2/CD2R (5 g/250 L) ϭ 37.43%. Precipitate at 0.012 g/mL ϭ 16.32%, 0.024 g/mL ϭ 20.30%, 0.049 g/mL ϭ 24.79%, 0.098 g/mL ϭ 37.52%, 0.195 g/mL ϭ 40.23%, 0.390 g/mL ϭ 50.04%, 0.780 g/mL ϭ 55.33%, 1.560 g/mL ϭ 59.97%, 3.125 g/mL ϭ 65.40%, 6.250 g/mL ϭ 71.87%, 12.50 g/mL ϭ 76.42%, 25.00 g/mL ϭ 80.20%, 50.00 g/mL ϭ 82.80%, 100.0 g/mL ϭ 87.44%, 200.0 g/mL ϭ 87.44%, 400.0 g/mL ϭ 87.61%, 800.0 g/mL ϭ 85.42%, 1600 g/mL ϭ 80.90%.
Against CD56ϩ cells. 2% DMSO in RPMI ϭ 7.10%, RPMI ϭ 8.36%, CspA (10 g/mL) ϭ 6.71%, PMA (50 ng/mL) ϭ 94.94%, CD2/CD2R (5 g/250 L) ϭ 31.46%. Precipitate at 0.012 g/mL ϭ 46.05%, 0.024 g/mL ϭ 46.20%, 0.049 g/mL ϭ 52.82%, 0.098 g/mL ϭ 58.69%, 0.195 g/mL ϭ 56.14%, 0.390 g/mL ϭ 61.41%, 0.780 g/mL ϭ 61.27%, 1.560 g/mL ϭ 64.19%, 3.125 g/mL ϭ 66.62%, 6.250 g/mL ϭ 68.65%, 12.50 g/mL ϭ 74.07%, 25.00 g/mL ϭ 77.67%, 50.00 g/mL ϭ 78.69%, 100.0 g/mL ϭ 80.30%, 200.0 g/mL ϭ 77.02%, 400.0 g/mL ϭ 72.12%, 800.0 g/mL ϭ 62.38%, 1600 g/mL ϭ 58.75%.
Fractions from E. angustifolia roots against CD4ϩ cells. DMSO ϭ 3.46%, RPMI ϭ 3.23%, CspA ϭ 4.38%, PMA ϭ 99.26%, PHA ϭ 5.36%, CD2/CD2R ϭ 25.79%. Ethanol precipitate at 38 pg/mL ϭ 3.68%, 1.5 ng/mL ϭ 3.60%, 6.1 ng/mL ϭ 5.37%, 24.4 ng/mg ϭ 14.68%, 98.5 ng/mg, 26.45%, 390 ng/mL ϭ 38.62%, 1.56 g/mL ϭ 42.14%, 6.25 g/mL ϭ 46.06%, 25 g/mL ϭ 55.21%, 100 g/mL ϭ 63.21%, 400 g/mL ϭ 54.82%, 1600 g/mL ϭ 34.55%.
IMMUNOSTIMULANT ACTIVITY OF ECHINACEA 634C
